A Phase 2/3 interventional study of BYM338/bimagrumab and Placebo in Sporadic Inclusion Body Myositis, sponsored by Novartis Pharmaceuticals. Completed at 38 sites in 10 countries. Open to participants aged 36 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-08-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Myositis, Inclusion Body with a site in United States — 4 open to participants now, 9 under way, 2 of them phase 3. Myositis, Inclusion Body · United States.
Among the 37 studies in Myositis, Inclusion Body with a site in United States, this one is the 3rd largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2013, is one of 6 in phase 2/3, and was the 18th registered.
65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.
Browse Myositis, Inclusion Body studies →4 of the 37 studies in Myositis, Inclusion Body with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Myositis International Health & Research Collaborative Alliance Foundation · Sites in United States
Ages 7+
Austin Neuromuscular Center · Sites in United States
Ages 45–75
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 2–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Myositis, Inclusion Body studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 36 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 13 · Phase 3 9
First in 1990; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 251 is above the median of 30 across 42 interventional studies indexed under Myositis, Inclusion Body.
Median enrollment 24 across the 27 interventional studies, 59 across the 10 observational. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 37 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 6 studies filed under Myositis, Inclusion Body — fewer than ten, so there is no comparison to draw.
2 of the studies in Myositis, Inclusion Body with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05046821University of California, IrvineSporadic Inclusion Body Myositis Natural History Study | 2027-03-31 |
| NCT06479863Austin Neuromuscular CenterEfficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis | 2027-05-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Myositis, Inclusion Body with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic inclusion body myositis (sIBM).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received study medication with BYM338 at 10 mg/kg from Day 1 to Week 52 and up to Week 104, administered by intravenous (i.v.) infusion every 4 weeks.
Drug: BYM338/bimagrumab
Participants received study medication with BYM338 at 3 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
Drug: BYM338/bimagrumab
Participants received study medication with BYM338 at 1 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
Drug: BYM338/bimagrumab
Participants received matching placebo to BYM338 from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
Drug: Placebo
Drug page: Bimagrumab
BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Change From Baseline in 6 Minute Walking Distance (6MWD) Test at Week 52
The 6MWD test measured the distance (in meters) that a participant walked in a 6 minute timeframe. A positive change from baseline indicates improvement.
Time frame: Baseline, Week 52
Estimated Within Treatment Group Lean Body Mass (LBM) Ratio at Week 52
LBM was measured via dual energy x-ray absorptiometry (DXA) and calculated as (LBM at Week 52/LBM at baseline)\*100 . A positive change from baseline indicates improvement.
Time frame: Baseline, Week 52
Change From Baseline in Quadriceps Quantitative Muscle Testing (QMT) on the Right Side at Week 52
Quadriceps muscle strength was measured by portable fixed dynamometry (PFD) on the right side. A negative change from baseline indicates deterioration.
Time frame: Baseline, Week 52
Change From Baseline in Sporadic Inclusion Body Myositis (sIBM) Functional Assessment (sIFA) Score at Week 52
Self-reported physical function was assessed by a newly developed patient reported outcome named sporadic inclusion body myositis (sIBM) functional assessment (sIFA). The sIFA consists of 11 items scored on an 11 point numerical rating scale from 0 (no difficulty) to 10 (unable to do) across 3 domains: upper body functioning, lower body functioning and general functioning. Participants completed the assessment where the recall period was the past week prior to completing the patient reported outcome (PRO). The total score on the sIFA scale ranges from 0 (minimum) to 110 (maximum). Higher values represent a worse outcome. A positive change from baseline indicates deterioration.
Time frame: Baseline, Week 52
Estimated Annual Number of Falls Per Patient Within Treatment Group
Participants documented any fall occurrences in a paper diary during the study.
Time frame: Week 52
Change From Baseline in Short Physical Performance Battery (SPPB) Score at Week 52
The SPPB evaluated lower extremities function by testing gait speed, ability to keep standing balance and time to rise from a chair five times. The sub-score for each test ranged from 0 to 4. The summary score, which was a summation of scores from the 3 tests, ranged from 0 to 12. An increase in score indicates improvement in physical performance. A negative change from baseline indicates deterioration.
Time frame: Baseline, Week 52
Participants were randomized into one of the four treatment arms in a 1:1:1:1 ratio.
| Milestone | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Started | 63 | 63 | 63 | 62 |
| Full analysis set | 63 | 63 | 63 | 62 |
| Completed | 54 | 55 | 56 | 57 |
| Not completed | 9 | 8 | 7 | 5 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study treatment | 0 | 0 | 0 | 1 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 3 | 3 | 2 |
| Withdrew: Adverse event | 3 | 5 | 3 | 1 |
| Milestone | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Started | 49 | 46 | 52 | 50 |
| Completed | 49 | 45 | 50 | 48 |
| Not completed | 0 | 1 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 2 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Milestone | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Started | 57 | 61 | 56 | 58 |
| Completed | 56 | 55 | 55 | 54 |
| Not completed | 1 | 6 | 1 | 4 |
| Withdrew: Adverse event | 1 | 4 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Non-compliance with study treatment | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 2 |
The 6MWD test measured the distance (in meters) that a participant walked in a 6 minute timeframe. A positive change from baseline indicates improvement.
| meters | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Change From Baseline in 6 Minute Walking Distance (6MWD) Test at Week 52 | 8.63 ± 10.934 | 9.63 ± 10.770 | -10.27 ± 10.718 | -8.96 ± 10.765 |
LBM was measured via dual energy x-ray absorptiometry (DXA) and calculated as (LBM at Week 52/LBM at baseline)\*100 . A positive change from baseline indicates improvement.
| Percentage | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Estimated Within Treatment Group Lean Body Mass (LBM) Ratio at Week 52 | 102.8 (101.4 to 104.2) | 100.4 (99.1 to 101.8) | 98.3 (97.0 to 99.6) | 97.2 (95.9 to 98.5) |
Quadriceps muscle strength was measured by portable fixed dynamometry (PFD) on the right side. A negative change from baseline indicates deterioration.
| newtons | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Quadriceps Quantitative Muscle Testing (QMT) on the Right Side at Week 52 | -12.44 ± 6.021 | -20.36 ± 5.843 | -14.89 ± 5.828 | -16.48 ± 5.830 |
Self-reported physical function was assessed by a newly developed patient reported outcome named sporadic inclusion body myositis (sIBM) functional assessment (sIFA). The sIFA consists of 11 items scored on an 11 point numerical rating scale from 0 (no difficulty) to 10 (unable to do) across 3 domains: upper body functioning, lower body functioning and general functioning. Participants completed the assessment where the recall period was the past week prior to completing the patient reported outcome (PRO). The total score on the sIFA scale ranges from 0 (minimum) to 110 (maximum). Higher values represent a worse outcome. A positive change from baseline indicates deterioration.
| score on a scale | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Sporadic Inclusion Body Myositis (sIBM) Functional Assessment (sIFA) Score at Week 52 | 1.74 ± 1.915 | 3.56 ± 1.876 | 6.12 ± 1.899 | 6.85 ± 1.895 |
Participants documented any fall occurrences in a paper diary during the study.
| Annual number of falls per participant | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Estimated Annual Number of Falls Per Patient Within Treatment Group | 4.33 | 4.02 | 4.70 | 5.13 |
The SPPB evaluated lower extremities function by testing gait speed, ability to keep standing balance and time to rise from a chair five times. The sub-score for each test ranged from 0 to 4. The summary score, which was a summation of scores from the 3 tests, ranged from 0 to 12. An increase in score indicates improvement in physical performance. A negative change from baseline indicates deterioration.
| score on a scale | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Short Physical Performance Battery (SPPB) Score at Week 52 | 0.0 ± 0.24 | 0.0 ± 0.23 | -0.5 ± 0.23 | -0.5 ± 0.23 |
Collected over up to 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BYM338/Bimagrumab 10 mg/kg | — | 21/63 (33.3%) | 63/63 (100%) |
| BYM338/Bimagrumab 3 mg/kg | — | 11/63 (17.5%) | 63/63 (100%) |
| BYM338/Bimagrumab 1 mg/kg | — | 18/63 (28.6%) | 63/63 (100%) |
| Placebo | — | 20/62 (32.3%) | 61/62 (98.4%) |
| Event | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| FALLInjury, poisoning and procedural complications | 2/63 | 2/63 | 4/63 | 1/62 |
| BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/63 | 3/63 | 1/63 | 3/62 |
| DIARRHOEAGastrointestinal disorders | 3/63 | 0/63 | 0/63 | 0/62 |
| DYSPHAGIAGastrointestinal disorders | 0/63 | 0/63 | 0/63 | 2/62 |
| TIBIA FRACTUREInjury, poisoning and procedural complications | 1/63 | 0/63 | 2/63 | 0/62 |
| SQUAMOUS CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/63 | 2/63 | 2/63 | 0/62 |
| ATRIOVENTRICULAR BLOCK SECOND DEGREECardiac disorders | 1/63 | 0/63 | 0/63 | 1/62 |
| VERTIGOEar and labyrinth disorders | 0/63 | 0/63 | 1/63 | 1/62 |
| RETINAL ARTERY OCCLUSIONEye disorders | 0/63 | 0/63 | 0/63 | 1/62 |
| LOWER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/63 | 0/63 | 0/63 | 1/62 |
| Event | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo |
|---|---|---|---|---|
| FALLInjury, poisoning and procedural complications | 47/63 | 55/63 | 54/63 | 52/62 |
| MUSCLE SPASMSMusculoskeletal and connective tissue disorders | 32/63 | 43/63 | 25/63 | 13/62 |
| DIARRHOEAGastrointestinal disorders | 32/63 | 28/63 | 20/63 | 11/62 |
| CONTUSIONInjury, poisoning and procedural complications | 14/63 | 23/63 | 22/63 | 22/62 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 15/63 | 14/63 | 19/63 | 15/62 |
| ACNESkin and subcutaneous tissue disorders | 12/63 | 19/63 | 8/63 | 6/62 |
| SKIN ABRASIONInjury, poisoning and procedural complications | 14/63 | 14/63 | 14/63 | 17/62 |
| FATIGUEGeneral disorders | 9/63 | 4/63 | 14/63 | 7/62 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 11/63 | 11/63 | 14/63 | 10/62 |
| BACK PAINMusculoskeletal and connective tissue disorders | 10/63 | 8/63 | 14/63 | 9/62 |
The Full Analysis Set (FAS), which included all randomized participants who had received at least one dose of study drug and had at least one post-baseline efficacy assessment, was analyzed.
| Age, Continuous(Years) | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 68.0 ± 7.93 | 66.5 ± 8.72 | 69.4 ± 7.91 | 68.4 ± 8.12 | 68.1 ± 8.20 |
| Sex: Female, Male(Participants) | BYM338/Bimagrumab 10 mg/kg | BYM338/Bimagrumab 3 mg/kg | BYM338/Bimagrumab 1 mg/kg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 22 | 21 | 23 | 23 | 89 |
| Male | 41 | 42 | 40 | 39 | 162 |
Ran from Sep 2013 to primary completion in Jan 2016, 27 months.
Results were first posted in May 2017, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimagrumab